FMO5 and type 2 diabetes mellitus: TZD pioglitazone enhances antioxidant defenses in T2D models by increasing SOD, catalase and glutathione peroxidase activities, while reducing ROS, TBARS, myeloperoxidase, lipid peroxidation and protein oxidation, and inhibiting NADPH oxidase [137, 139, 142].